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Abstract. Autologous and single donor allogenic platelet preparations are 
increasingly being used in many areas of regenerative medicine. However, there are 
few properly controlled randomized clinical trials, and the preparation, content and 
characteristics of platelet preparations are generally poorly defined and controlled. 
The Platelet Physiology Subcommittee of the Scientific and Standardization 
Committee (SSC) of the ISTH formed a working party of experts with the aim of 
producing consensus recommendations for guidance on the use of platelets in 
regenerative medicine. Due to a lack of investigations that provide definitive 
evidence for the efficacy, definition and use of different platelet preparations in 
regenerative medicine, there were insufficient data to develop evidence-based 
guidelines. Therefore, the RAND method was used, which obtains a formal 
consensus among experts particularly when scientific evidence is absent, scarce 
and/or heterogeneous. Using this approach, each expert scored as "appropriate", 
"uncertain" or "inappropriate" a series of 45 statements about the practice of 
regenerative medicine with platelets, which included different sections on general 
aspects, platelet preparations, clinical trial design; and potential utility in different 
clinical scenarios. After presentation and public discussion at SSC meetings, the 
assessments were further refined to produce final consensus recommendations 
which is the subject of the present report.  
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Introduction 
Platelet-Rich Plasma (PRP), an autologous or allogeneic derivative of whole blood 
that contains a supra-physiological concentration of platelets, has gained increasing 
attention in both the scientific literature and the wider media for its potential 
application as a regenerative adjunct therapy [1-5]. The platelet -granules provide a 
vast array of growth factors and cytokines that are important in wound healing [1]. 
These factors can promote local angiogenesis, stem cell homing, local cell migration, 
proliferation and differentiation coupled with the deposition of matrix proteins, such 
as collagen, which all play a key role in enabling the restoration of normal tissue 
structure and function. The regenerative effect of PRP exerted by producing a local 
environment for tissue regeneration has been supported by in vitro and in vivo 
studies that suggest a positive influence on the migration and proliferation of a 
number of cell types. Although PRP therapy is increasingly popular and more and 
more widely employed, clinical use initially centred on its potential application in 
dental and maxillofacial surgery. The regenerative effects of PRP on bone, cartilage, 
skin, tendon and muscle have also attracted interest in orthopaedic and plastic 
surgery where restoration of poorly vascularised and damaged tissue is a critical 
determinant of successful clinical outcome [6-12]. Given the complexity of the 
material, the rudimentary knowledge of the mechanism of action of PRP and the 
limitations of current studies, any future clinical trial should be carefully designed to 
both accurately determine any clinical effects, and importantly should use disease-
specific outcome tools. Imprecision in effect size estimates from underpowered 
studies with PRP has also undoubtedly led to unreliable conclusions [2]. The field is 
also plagued with poor standardization and variability in the methods used to 
generate PRP with variability in the terminology, purity, content and quality of 
products utilized [13, 14]. Depending upon its method of preparation, PRP can also 
be defined as platelet-enriched plasma(PeRP), platelet-rich concentrate(PRC), 
platelet concentrate, leukocyte-rich PRP(L-PRP), platelet-rich fibrin(PRF), platelet-
rich in growth factors(PRGF), platelet-rich fibrin matrix(PRFM), autologous 
concentrated plasma(ACP), platelet gel, pure platelet-rich plasma(PurePRP) or 
platelet releasate etc. [15-19]. Platelet products therefore have varying 
concentrations of blood cells (platelets, leukocytes and erythrocytes) plasma or 
fibrinogen. Unsurprisingly, the content, purity and hence the biological properties of 
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those products therefore vary widely and impact upon their potential efficacy. 
Several clinical trials have therefore been conducted without clear definition or 
quantification of the PRP biological properties, leading to varying efficacy and 
outcomes.  
There are also many types of commercial PRP preparation devices resulting 
in further variation in product content [20]. PRP regenerative properties are based on 
the production and release of bioactive proteins, including multiple growth and 
differentiation factors, upon platelet activation. However, the role of other cells that 
may be present in PRP, such as leukocytes and erythrocytes, is still unclear and 
cannot be excluded. The presence of leukocytes may have great impact on the 
biology of these preparations, not only because of their immune and antibacterial 
properties, but also because they are key players in tissue healing and local growth 
factor regulation [21]. PRP also implies the application of autologous plasma along 
with platelet-derived proteins. Therefore, it promotes the development of a fibrin 
scaffold at the desired location that can act as a temporary matrix to assist repair of 
the injured tissue. Defining the potential role(s) of all the bioactive factors present in 
any platelet preparation is therefore essential to understand the biological activities.  
Autologous PRP can be prepared in a laboratory, operating theatre or a clinic 
room from anticoagulated blood collected at the time of the therapeutic application. 
Trisodium citrate is the most widely used anticoagulant with few negative effects on 
PRP preparation. ACD (acid citrate dextrose) and CPD (citrate phosphate dextrose), 
with and without adenine (ACD-A and CPD-A), are also effective anticoagulants. 
EDTA is not usually recommended for PRP preparation as this causes platelet 
swelling and activation. Traditionally, a relatively pure preparation and good yield of 
PRP can be easily obtained in a single step by centrifugation of anticoagulated blood 
at low force (170-200 g) for 10 minutes at room temperature [22]. For clinical 
applications there are essentially three main methods available that can rapidly 
provide a sterile PRP product: 1) Gravitational centrifugation techniques 2) Standard 
cell separators and 3) Autologous selective filtration technology (plateletpheresis). 
Standard cell separators and salvage devices generally operate on a full unit of 
blood. In general, they use continuous flow centrifuge bowl or continuous flow disk 
separation technology coupled with hard and soft centrifugation steps. High g-force 
centrifugation is normally used to isolate the buffy coat layer containing platelets and 
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leukocytes. Differences in g-force and centrifugation time used in each preparation 
technique will also result in significant differences in yields, concentration, purity, 
viability and activation status of the isolated platelets but also affect eventual clinical 
efficacy. PRP must also be activated for the platelets to release their α-granule 
contents, with the clot providing a scaffold to capture the secreted proteins and 
maintain their presence at the application site. This introduces another set of 
variables including method of activation (e.g. thrombin, re-calcification, etc), duration 
of activation and whether this should be performed prior to clinical application. 
Although popular and widely used, the use of platelets in regenerative medicine is 
clearly poorly standardized. Although some guidelines have been published, if this 
field is to progress then standardization of the methods for the generation of the 
various platelet-rich preparations and evidence based guidelines for future clinical 
trials are urgently required [23, 24]. In January 2016, the Platelet Physiology 
Subcommittee of the ISTH formed a working Party of 10 well known experts in the 
field of regenerative medicine with the aim of producing a series of consensus 
recommendations for standardizing the use of platelets in regenerative medicine.  
The working party then used a formal consensus method (RAND method) to develop 
its final recommendations.  
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Methods 
The RAND method – developed by the RAND corporation in the 1980s – obtains a 
consensus among expert groups about the appropriateness of healthcare 
interventions when scientific evidence is absent, scarce or heterogeneous [25].  A 
series of statements about platelets in regenerative medicine were therefore 
formulated and each member of the working party then scored each one for 
appropriateness from 1 (completely inappropriate) to 9 (fully appropriate). Individual 
scores were blinded to other panel members and the two extreme scores (highest 
and lowest) then discarded. The median of the remaining 8 scores were then 
calculated and the statements classified as either inappropriate (scores 1-3), 
uncertain (4-6) or appropriate (7-9).  The panel was also asked to give any further 
comments of relevance to this field. Recommendations were then presented at ISTH 
SSC meetings and it was agreed that these could form the basis of a consensus 
document.  
The recommendations of the working party on the use of Platelets in regenerative 
medicine derive from 45 statements grouped into four main sections:  
i) General aspects;   
ii) Platelet preparation;   
iii) Clinical trial design;  
iv) Utility of platelets in different clinical scenarios.  
Overall 26 statements were scored as appropriate (11 statements were with 
complete agreement with an additional 15 statements also in agreement after 
removal of the 2 extreme scores) and 19 statements were judged as uncertain. 
No statements were judged as inappropriate. The term PRP used in the 
statements below encompasses all platelet and platelet-related products used for 
regenerative medicine. 
Results 
General aspects 
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1. It is uncertain whether PRP preparations (autologous or allogeneic) are 
clinically useful in tissue regenerative techniques (median score 6, range 5-8). 
 
2. It is uncertain whether platelet gels or clots are clinically useful in 
regenerative medicine (median score 6, range 5-7). 
 
3. It is uncertain whether platelet-rich fibrin is clinically useful in regenerative 
medicine (median score 6, range 5-7). 
 
4. Appropriate The term PRP is a confusing, too general and incomplete 
terminology (median score 8.5, range 7-9). 
 
5. Appropriate Autologous/Allogeneic sterile PRP preparations are clinically 
safe (median score 7.5, range 5-8). 
 
6. Appropriate Clinical Preparations of PRP are poorly standardized (median 
score 8.5, range 7-9 with complete agreement by entire panel). 
 
7. Appropriate The content, purity and biological properties of PRP all vary 
widely and will impact upon their clinical efficacy (median score 8.5, range 6-
9). 
 
8. Appropriate Many trials or studies fail to fully define the content, purity and 
biological properties of platelet preparations (median score 9, range 8-9 with 
complete agreement by entire panel). 
 
Platelet preparation 
1. It is uncertain whether PRP should be prepared from citrate anticoagulated 
whole blood (median score 5.5, range 3 -7). 
 
2. It is uncertain whether PRP should be prepared from ACD anticoagulated 
whole blood (median score 6.5, range 4-8). 
 
3. It is uncertain whether PRP should be prepared from CPD anticoagulated 
whole blood (median score 4.5, range 2-7). 
 
4. Appropriate EDTA anticoagulant should not be used for PRP preparation 
(median score 8, range 6-9). 
 
5. It is uncertain whether PRP should ideally be produced by low g 
centrifugation for short periods (e.g. 170 g for 10 minutes) to maximise 
platelet yield and minimise cellular contamination (median score 5, range 5-8). 
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6. Appropriate Platelet concentration, yield and recovery are dependent upon 
centrifugation protocol and collection methods utilised (median score 8, range 
8-9 with complete agreement by entire panel). 
 
7. It is uncertain whether PRP once prepared is stable for clinical use up to 6 
hours post preparation (median score 6, range 4-8). 
 
8. It is uncertain whether PRP must be activated for platelets to release their 
granule contents before application (median score 5, range 4-8). 
 
9. Appropriate In some applications collagen-rich tissues may also activate 
PRP and eliminate the need for a pre-application activation step (median 
score 7, range 5-8). 
 
Clinical trial design 
Clinical trials on the use of platelets in regenerative medicine should be adequately 
powered and controlled with some essential design requirements including:- 
1) Appropriate Randomized placebo controlled design (median score 8, range 
7-9). 
 
2) Appropriate Sample size calculation based on clear predefined endpoints 
(median score 8.5, range 7-9 with complete agreement by entire panel). 
 
3) Appropriate Clear inclusion/exclusion criteria (median score 9, range 7-9 with 
complete agreement by entire panel). 
 
4) Appropriate A homogeneous study population (median score 8, range 7-9). 
 
5) Appropriate Standardised clinical assessments (median score 9, range 6-9 
with complete agreement by entire panel). 
 
6) Appropriate Clinical endpoints objectively measured (median score 9, range 
7-9). 
 
7) Appropriate Validated PRP production and delivery methods (median score 
9, range 6-9). 
 
8) Appropriate Details on the applied treatment including number of platelets, 
number of applications, duration of treatment etc (median score 9, range 7-9 
with complete agreement by entire panel). 
 
9) Appropriate Robust clear clinical outcomes (median score 9, range 7-9). 
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10) Appropriate Standardized post treatment follow up protocol (median score 9, 
range 7-9 with complete agreement by entire panel). 
 
11) Appropriate Full description of PRP preparation methodology (median score 
9, range 8-9 with complete agreement by entire panel). 
 
12) Appropriate Details of the amount of autologous blood collected (median 
score 9, range 7-9). 
 
13) Appropriate Baseline number, volume and concentration of platelets utilised 
(median score 8, range 7-9 with complete agreement by entire panel)  
 
14) It is uncertain whether the overall yield of platelets obtained during PRP 
preparation should be reported (median score 6.5, range 6-9). 
 
15) Appropriate The purity of the final PRP preparation should be reported, i.e. 
how many RBC and WBC are contaminating the PRP and whether the 
preparation contains plasma (median score 8, range 7-9 with complete 
agreement by entire panel).  
 
16) Appropriate A measurement of PRP quality is required – i.e. platelet 
activation status prior to clinical use (to clarify if platelets have already lost 
their granular content) (median score 7, range 5-9). 
 
17) It is uncertain whether the measurement of Growth Factor content of the 
PRP preparation used should be reported (median score 6.5, range 4-9). 
 
18) Appropriate The activation procedure, if used, should be reported (median 
score 9, range 7-9). 
 
19) Appropriate A new classification system for PRP is required taking into 
account all key variables (median score 9, range 7-9). 
Utility in different clinical scenarios. 
1) It is uncertain whether PRP can be utilised to treat burn injuries (median 
score 6.5, range 5-7). 
 
2) Appropriate PRP can be utilised for general wound healing (median score 7, 
range 5-7). 
 
3) It is uncertain whether PRP can be utilised for treating tendon Injuries 
(median score 5.5, range 5-8). 
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4) It is uncertain whether PRP can be used for acute muscle injuries (median 
score 5, range 5-6). 
 
5) It is uncertain whether PRP can be utilised for bone healing (median score 
6, range 4-7). 
 
6) It is uncertain whether PRP can be utilised in Maxillofacial injuries (median 
score 5.5, range 4-8). 
 
7) It is uncertain whether PRP can be utilised for treating Sports injuries 
(median score 5.5, range 5-7). 
 
8) It is uncertain whether PRP can be utilised to treat osteoarthritis (median 
score 6.5, range 5-8) 
 
9) It is uncertain whether PRP can be utilised to prevent skin ageing as a 
beauty therapy (median score 4, range 2-5) 
 
All of these statements are also summarized in supplementary table 1. 
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Proposed New Classification System for PRP and related products 
The authors of this guideline suggest a new classification system, which incorporates 
previous classification systems, and includes the preparation method technique[16, 
18].  
Activation is divided into three subcategories: 
- I for PRP application without activator  
- II  for the use of PRP with activation 
- III for use of frozen-thawed preparations 
 
Platelet concentrates are subdivided into three categories (A, B and C) based on the 
platelet count range in the samples. The three categories are:  
A Platelet count < 900 x103 /µl 
B Platelet count 900 – 1700 x103 /µl 
C Platelet count > 1700 x103 /µl 
 
The preparation methods are classified into three categories: 
1 The Gravitational centrifugation techniques  
2 Standard cell separators  
3 Autologous selective filtration technology (plateletpheresis) 
The modified classification is summarized in table 1. This includes the activation 
method if used, the total volume used, the frequency of dosing and subcategories of 
activation, platelet concentration and preparation technique and would include the 
overall average counts and range(low–high) of platelets, red cells and differential 
leukocyte counts(neutrophils, lymphocytes and monocytes). 
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Conclusions 
Autologous or allogeneic platelet administration remains an attractive and popular 
strategy in many clinical scenarios given the cost-effective, minimally invasive and 
safe nature of this therapy [1]. The statements presented here should contribute to 
improve the standardization and design of future clinical trials using platelets in 
regenerative medicine and agree with some parts of recent recommendations [23, 
24]. Future trials should not only be appropriately controlled and adequately 
powered, but also take into account the content and quality control of the platelet 
preparations to ensure that clear correlations between the products and outcomes 
are established [23, 24, 26-28]. Further studies into the mechanism of platelet tissue 
regeneration and optimal platelet preparation may help elucidate the best 
combination of bioactive factors to achieve maximal regenerative activity [29]. It will 
be important that guidelines such as this one should also be reviewed and updated 
in the future as the field continually changes and evolves. 
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Class Leukocytes 
+ = > 1% 
Red Cells 
+ = > 10% 
Activation Platelet 
Concentration 
Preparation 
category 
PRP 
 
Red-PRP 
-  - 
 
+ 
I 
II 
III 
A 
B 
C 
1 
2 
3 
L-PRP 
 
Red-L-PRP 
+  - 
 
+ 
I 
II 
III 
A 
B 
C 
1 
2 
3 
PRF 
 
Red-PRF 
- - 
 
+ 
I 
II 
III 
A 
B 
C 
1 
2 
3 
L-PRF 
 
Red-L-PRF 
+ - 
 
+ 
I 
II 
III 
A 
B 
C 
1 
2 
3 
 
Table 1. A proposed new PRP classification system. This includes the activation 
method if used, the total volume used, the frequency of dosing) and subcategories of 
activation, platelet concentration and the preparation techniques - 1) Gravitational 
centrifugation techniques 2) Standard cell separators and 3) Autologous selective 
filtration technology (plateletpheresis). (e.g recalcified 5 ml (x1) – Red-L-PRP IB1 
has been used in the PATH-2 trial [26] and would include the overall average counts 
and range (low – high) of platelets, red cells and differential leukocyte counts 
(neutrophils, lymphocytes and monocytes). (Abbreviations: PRP= platelet rich 
plasma; Red-PRP= Red Cell Rich platelet Rich Plasma; L-PRP= Leukocyte rich 
platelet rich plasma; Red-L-PRP Red Cell and Leukocyte rich platelet rich plasma. 
PRF= Platelet Rich Fibrin; Red-PRF= Red cell rich Platelet Rich Fibrin; L-PRF= 
Leukocyte rich platelet rich fibrin; Red-L-PRF= Red cell and Leukocyte rich platelet 
rich fibrin. 
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Supporting Information 
General Comments from the panel :- 
1) Clearly the application procedure for these products is as important as the 
product "per se". For example, volume, injection techniques, sonography assisted 
interventions or debridement in wound care.  
2)  We do not know if platelet dosage is more important than platelet enrichment, 
or if the balance between both plasma and platelet derived molecules determine the 
efficacy of the product.   
3) It may be also important to consider the status of host tissue being treated 
including chronicity, inflammatory or degenerative status.   
4) We also need more research before deciding which anticoagulants are 
optimal, what growth factors or chemokines or cytokines are important; thus quality 
control  and how to optimally implement this is still challenging. 
5) Recent research in ulcer care has also focussed on the lipidomic content of 
PRP, which is largely ignored in the majority of studies.  
6) In addition, the age of patients and metabolic associated co-morbidities, or 
systemic inflammatory conditions (e.g. in burns patients) may significantly influence 
the quality of autologous PRP [30].  
7) In complex pathologies such as tendinopathies or osteoarthritis the effort to 
advance in PRP therapies should be accompanied by identifying different 
phenotypes.   
8) In oral and maxillofacial surgery, the various forms of PRF (mostly the L-PRF 
family) are developing very strongly as an inexpensive, open-access and efficient 
surgical adjuvant.  
9) The effects in regenerative medicine of PRF are more dependent on the fibrin 
architecture (which may be dependent on the platelets and defines the bio-
mechanical properties of the material) and the cell content (particularly the 
proportions of various leukocytes and circulating cells). All of these will participate in 
the definition of the "biological signature for growth factors release" of each kind of 
product and its final clinical potential. 
10) There remains so much to investigate about appropriate number of (activated) 
platelets, quality of platelets, addition (or not) of leukocytes, multiple to single 
applications and this for all different indications. 
11) The role of white and red blood cells may be very important in PRP and need 
to be properly investigated?  
17 
 
12) We will need profound basic studies and randomized clinical trials to really 
verify the use of PRP or any other platelet preparations in any clinical application. 
RCT should include deep characterization of injected products with GF quantification 
in link with the disease treated. 
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Supplementary Material 
 
Supplementary Table 1. A summary of the median scores and ranges of the 
working party for each of the 45 statements in the RAND survey about platelets in 
regenerative medicine. Each statement is classified as either inappropriate (scores 
1-3), uncertain (4-6) or appropriate (7-9). The term PRP used in the statements 
encompasses all platelet and platelet-related products used for regenerative 
medicine. 
 
RAND survey statements Median Score and 
Range 
Classification 
General Aspects   
PRP preparations are clinically useful in 
tissue regenerative techniques 
6 (5-8) Uncertain 
Platelet gels or clots are useful in 
regenerative medicine 
6 (5-7) Uncertain 
Platelet-rich fibrin is clinically useful in 
regenerative medicine 
6 (5-7) Uncertain 
Autologous/Allogeneic sterile PRP 
preparations are clinically safe 
7.5 (5-8) Appropriate 
The term PRP is a confusing, too general 
and incomplete terminology 
8.5 (7-9) Appropriate 
Clinical preparations of PRP are poorly 
standardized 
8.5 (7-9) 
Complete agreement 
Appropriate 
The content, purity and biological 
properties of PRP all vary widely and will 
impact upon their clinical efficacy 
8.5 (6-9) Appropriate 
Many trials or studies fail to define the 
content, purity and biological properties of 
platelet preparations 
9 (8-9) 
Complete agreement 
Appropriate 
Platelet Preparation   
PRP should be prepared from citrate 
anticoagulated blood 
5.5 (3 -7) Uncertain 
PRP should be prepared from ACD 
anticoagulated blood 
6.5 (4-8) Uncertain 
PRP should be prepared from CPD 
anticoagulated blood 
4.5 (2-7) Uncertain 
EDTA anticoagulant should not be used 
for PRP preparation 
8 (6-9) Appropriate 
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PRP should be ideally produced by low g 
centrifugation for short periods (e.g. 170 g 
for 10 minutes to maximise platelet yield 
and minimise cellular contamination 
5 (5-8) Uncertain 
Platelet concentration, yield and recovery 
are dependent upon centrifugation 
protocol and collection methods utilised 
8 (8-9) 
Complete agreement 
Appropriate 
PRP once prepared is stable for clinical 
use up to 6 hours post preparation 
6 (4-8) Uncertain 
PRP must be activated for platelets to 
release their granule contents before 
application 
5 (4-8)  Uncertain 
In some applications collagen-rich tissues 
may also activate PRP and eliminate the 
need for a pre-application activation step 
7 (5-8) Appropriate 
Clinical Trial Design   
Clinical trials on the use of platelets in 
regenerative medicine should be 
adequately powered and controlled with 
some essential design requirements 
including :- 
  
Randomized placebo controlled design 8 (7-9) Appropriate 
Sample size calculation based on clear 
predefined endpoints 
9 (7-9) 
Complete agreement 
Appropriate 
Clear inclusion/exclusion criteria 9 (7-9) 
Complete agreement 
Appropriate 
A homogeneous study population 8 (7-9) Appropriate 
Standardised clinical assessments 9 (7-9) 
Complete agreement 
Appropriate 
Clinical endpoints objectively measured 9 (7-9) Appropriate 
Validated PRP production and delivery 
methods 
9 (6-9) Appropriate 
Details on the applied treatment including 
number of platelets, number of 
applications, duration of treatment etc 
9 (7-9) 
Complete agreement 
Appropriate 
Robust clear clinical outcomes 9 (7-9) Appropriate 
Standardized post treatment follow up 
protocol  
9 (7-9) 
Complete agreement 
Appropriate 
Details of the amount of autologous blood 
collected 
9 (7-9) Appropriate 
Baseline number, volume and 
concentration of platelets utilised 
8 (7-9) Appropriate 
The overall yield of platelets obtained 
during PRP preparation should be 
reported 
6.5 (6-9) Uncertain 
The purity of the final PRP preparation 
should be reported, i.e. how many RBC 
8 (7-9) 
Complete agreement 
Appropriate 
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and WBC are contaminating the PRP and 
whether the preparation contains plasma 
A measurement of PRP quality is required 
– i.e. platelet activation status prior to 
clinical use (to clarify if platelets have 
already lost their granular content) 
7 (5-9) Appropriate 
The measurement of Growth Factor 
content of the PRP preparation used 
should be reported 
6.5 (4-9) Uncertain 
The activation procedure if used should be 
reported 
9 (7-9) Appropriate 
A new classification system for PRP is 
required taking into account all key 
variables 
9 (7-9) Appropriate 
Utility in different clinical scenarios   
PRP can be utilised to treat burn injuries 6.5 (5-7) Uncertain 
PRP can be utilised for general wound 
healing 
7 (5-7) Appropriate 
PRP can be utilised for tendon injuries 5.5 (5-8) Uncertain 
PRP can be utilised for acute muscle 
injuries 
5 (5-6) Uncertain 
PRP can be utilised for bone healing 6 (4-7) Uncertain 
PRP can be utilised for maxillofacial 
injuries 
5.5 (4-8) Uncertain 
PRP can be used for treating sports 
injuries 
5.5 (5-7) Uncertain 
PRP can be used to treat osteoarthritis 6.5 (5-8) Uncertain 
PRP can be used to prevent skin ageing 
as a beauty therapy 
4 (2-5) Uncertain 
 
 
 
 
 
